A Phase 2 interventional study of PF-00547659 in Crohn's Disease, sponsored by Shire. Completed at 112 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-06-03.
Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies in Crohn Disease by Takeda — 12 open to participants now, 14 under way, 7 of them phase 3. Crohn Disease · Takeda.
Among the 86 studies in Crohn Disease by Takeda, this one is the 12th largest by enrollment of the 51 interventional ones that give a count, is one of 2 that started in 2011, is one of 13 in phase 2, and was the 10th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →12 of the 86 studies in Crohn Disease by Takeda are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United Kingdom
Ages 18–75
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States, China, Czechia and 5 more countries
Ages 18–75
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 14 · Phase 3 25 · Phase 4 10
First in 2000; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 268 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 100 across the 51 interventional studies, 319 across the 34 observational. Of the 66 that completed or were terminated, 37 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
6 of the studies in Crohn Disease by Takeda that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT04779320Phase 3TakedaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | 2027-09-13 |
| NCT06233461TakedaA Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease | 2027-02-17 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06045754TakedaA Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease | 2027-06-28 |
Add all 6 to your calendar (.ics) → With an account.
Among the 86 studies in Crohn Disease by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study provides open-label drug to eligible patients who have completed a prior study of PF-00547659. The primary endpoint for this study is long-term safety.
The rationale for conducting this open-label extension (OLE) study is primarily to evaluate long term safety of PF 00547659. This protocol also provides the opportunity for continued treatment for subjects responding to treatment from the feeder study. It also provides an opportunity for initial treatment for subjects randomized to placebo in the feeder study. This is a multi center Phase 2, open label, safety extension study for feeder studies which evaluate PF 00546759 in subjects with moderate to severe Crohn's disease. Subjects eligible for this study will have completed the 12 week double blind induction period in study A7281006 and will be stratified by responders or non responders based on change in CDAI in that study, without unblinding treatment assignment from study A7281006. Additionally, subjects who have completed study A7281008 with a clinical response, as defined by that protocol, will also be eligible for this study and treated as "responders". All subjects entering this study must have discontinued immunosuppressant therapy.
Subjects entering this study will be given a 75 mg SC dose at baseline and then every 4 weeks through Week 72. After the active treatment period, the subjects will enter a 24 month follow up period including 6 monthly visits followed by 18 month extended contact (every 6 month telephone contacts). At Week 96, subjects will undergo an End of Study visit but will continue the every 6 month telephone contacts until Week 168.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects eligible for this study will have completed the 12 week double blind induction period in study A7281006 and will be stratified by responders or non responders based on change in CDAI in that study, without unblinding treatment assignment from study A7281006. Additionally, subjects who have completed study A7281008
Drug: PF-00547659
75 mg SC once monthly for 72 weeks. Subjects may escalate to 225 mg or de-escalate to 22.5 mg one time.
Number of Participants With On-Treatment Adverse Events (AEs), AEs Led to Withdrawal, and Serious Adverse Events (SAEs)
AEs included adverse drug reactions, illnesses with onset during the study, exacerbation of previous illnesses, clinically significant changes in physical examination findings and abnormal objective test findings (ECG, laboratory). An SAE was defined as any AE at any dose that resulted in death; was life threatening (immediate risk of death); required in-subject hospitalization or prolongation of existing hospitalization; resulted in a persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); or resulted in congenital anomaly/birth defect.
Time frame: From start of study treatment up to Week 72 (Treatment Period)
Number of Participants With Positive Anti-Drug (PF-00547659) Antibodies
Positive Anti-Drug Antibodies result was defined as ADA titre value greater than or equal to (\>=) 4.64 at at least one of the time points.
Time frame: Baseline up to Week 96
Serum Trough Concentrations of PF-00547659 Versus Time
Serum trough concentrations of PF-00547659 were analyzed using population Pharmacokinetic (PK) methodology.
Time frame: Week 4,8,12,16,20,24,28,32,36,40,44,48,52,56,60,64,68,72,76,80,84,88,92,96
The study was conducted at 81 centers in Austria, Belgium, Canada, France, Germany, Japan, Netherlands, Norway, Poland, Republic of Korea, Serbia, Slovakia, South Africa, Spain and United States between 22 July 2011 (first participant first visit) and 27 July 2016 (last participant last visit).
| Milestone | PF-00547659 75 mg |
|---|---|
| Started | 268 |
| Completed | 149 |
| Not completed | 119 |
| Withdrew: Death | 2 |
| Withdrew: Insufficient clinical response | 22 |
| Withdrew: Lost to follow-up | 12 |
| Withdrew: Withdrawal by subject | 47 |
| Withdrew: Other (unspecified) | 7 |
| Withdrew: Withdrawn due to pregnancy | 1 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Adverse event(related to study drug) | 8 |
| Withdrew: Adverse event(not related to study drug) | 18 |
AEs included adverse drug reactions, illnesses with onset during the study, exacerbation of previous illnesses, clinically significant changes in physical examination findings and abnormal objective test findings (ECG, laboratory). An SAE was defined as any AE at any dose that resulted in death; was life threatening (immediate risk of death); required in-subject hospitalization or prolongation of existing hospitalization; resulted in a persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); or resulted in congenital anomaly/birth defect.
| Participants | PF-00547659 75 mg |
|---|---|
| Participants With AEs | 249 |
| Participants With AEs Led to Withdrawal | 53 |
| Participants With SAEs | 80 |
Positive Anti-Drug Antibodies result was defined as ADA titre value greater than or equal to (\>=) 4.64 at at least one of the time points.
| Participants | PF-00547659 75 mg |
|---|---|
| Number of Participants With Positive Anti-Drug (PF-00547659) Antibodies | 63 |
Serum trough concentrations of PF-00547659 were analyzed using population Pharmacokinetic (PK) methodology.
| nanogram per milliliter (ng/mL) | PF-00547659 75 mg |
|---|---|
| Week 4 | 6673 ± 6634.2 |
| Week 8 | 6064 ± 4455.3 |
| Week 12 | 8040 ± 6293.1 |
| Week 16 | 9563 ± 7285.4 |
| Week 20 | 10400 ± 8438.6 |
| Week 24 | 10450 ± 7934.6 |
| Week 28 | 10780 ± 9211.0 |
| Week 32 | 11920 ± 10675 |
| Week 36 | 12460 ± 9717.1 |
| Week 40 | 12570 ± 10077 |
| Week 44 | 12960 ± 10999 |
| Week 48 | 13170 ± 11108 |
| Week 52 | 13560 ± 11388 |
| Week 56 | 13930 ± 11191 |
| Week 60 | 14130 ± 11095 |
| Week 64 | 14360 ± 11290 |
| Week 68 | 14990 ± 12883 |
| Week 72 | 13910 ± 10554 |
| Week 76 | 10520 ± 10082 |
| Week 80 | 3555 ± 5339.8 |
| Week 84 | 1129 ± 2634.7 |
| Week 88 | 403.8 ± 1522.6 |
| Week 92 | 154.2 ± 1001.9 |
| Week 96 | 54.73 ± 487.07 |
Collected over From Start of Study Treatment up to Safety Follow up (Week 96). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-00547659 75 mg | 2/268 (0.7%) | 118/268 (44%) | 206/268 (76.9%) |
| Event | PF-00547659 75 mg |
|---|---|
| Crohn's diseaseGastrointestinal disorders | 44/268 |
| Anal abscessInfections and infestations | 10/268 |
| Anal fistulaGastrointestinal disorders | 7/268 |
| IleusGastrointestinal disorders | 4/268 |
| Small intestinal obstructionGastrointestinal disorders | 4/268 |
| PneumoniaInfections and infestations | 4/268 |
| Abdominal painGastrointestinal disorders | 3/268 |
| NauseaGastrointestinal disorders | 3/268 |
| VomitingGastrointestinal disorders | 3/268 |
| Clostridium difficile infectionInfections and infestations | 3/268 |
| Event | PF-00547659 75 mg |
|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 83/268 |
| Crohn's diseaseGastrointestinal disorders | 79/268 |
| NasopharyngitisInfections and infestations | 54/268 |
| Abdominal painGastrointestinal disorders | 49/268 |
| HeadacheNervous system disorders | 35/268 |
| NauseaGastrointestinal disorders | 32/268 |
| Back painMusculoskeletal and connective tissue disorders | 28/268 |
| PyrexiaGeneral disorders | 27/268 |
| DiarrhoeaGastrointestinal disorders | 24/268 |
| VomitingGastrointestinal disorders | 23/268 |
The modified intent-to-treat (mITT) population included all enrolled participants who received at least 1 dose of investigational product.
| Age, Continuous(year) | PF-00547659 75 mg |
|---|---|
| Mean | 36.5 ± 11.7 |
| Sex: Female, Male(Participants) | PF-00547659 75 mg |
|---|---|
| Female | 151 |
| Male | 117 |
Showing the first 100 of 112 sites across 15 countries. Choose a country and city above to see the rest.
Ran from Jul 2011 to primary completion in Jul 2016, 60 months.
Results were first posted in Aug 2017, 1 year 1 month after primary completion.
Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 60 months is above that.
Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ontamalimab